Taking a compounded GLP-1 medication isn’t the same thing as your pharmacy filling a cheaper, generic version of the drug ...

It turns out that the anti-obesity space isn't growing as fast as Eli Lilly or analysts anticipated, resulting in ...

Sales of Lilly’s top-selling product, the diabetes treatment Mounjaro, jumped 60% to $3.53 billion in the final quarter of ...

Zepbound (tirzepatide) is only available on prescription for people with obesity, or those with overweight. Learn how to get Zepbound online, in-person, and through the drug’s manufacturer, Eli ...

Medicare drug plans can now cover Eli Lilly & Co.’s obesity drug Zepbound as a treatment for obstructive sleep apnea, news that’s expected to prove a big boost for the drug company.

Zepbound is the newest GLP-1 medication to be approved by the Food and Drug Administration (FDA) for weight loss. It’s available only by prescription for people with a body mass index (BMI) of ...

Zepbound's market share stands at just over 50%, according to IQVIA data shared by an analyst, with Lilly having started advertising the drug in November. Lilly could leverage its December data ...

Kisunla looks particularly attractive due to the significant unmet need in AD. These relatively new approvals ... Even with Eli Lilly's Mounjaro and Zepbound not growing as fast as many ...

We could point out that tirzepatide, the active ingredient in Mounjaro and Zepbound, is still undergoing ... for such products as Alzheimer's disease (AD) treatment Kisunla, ulcerative colitis ...